Valuation
- Market cap
- 184,045,000
- Revenue TTM
- $0
- Net income TTM
- $-20,510,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 37,100
- Avg volume
- 13,580
- Day's range
- $11.50 – $12.23
- Shares out
- 15,453,000
- Stochastic %K
- 74%
- Beta
- 1.15
- Analysts
- —
- Price target
- —
Company profile
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company ha...
Show more
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://satellos.com
- Address
- Royal Bank Plaza, Suite 2800 South Tower 200 Bay Street, Toronto, Canada
Latest news
No headlines yet.
